NICE Recommends Gilead’s Harvoni
The National Institute for Health and Care Excellence (NICE) have announced draft guidelines recommending Gilead’s Harvoni for regulatory approval. If approved, the combination therapy (ledipasvir-sofosbuvir) will be available to treat NHS patients with hepatitis C in England and Wales. Specifically, the drug has been recommended for the treatment of adults with genotype 1 or 4